{"id":"tp-03","safety":{"commonSideEffects":[{"rate":"null","effect":"Conjunctival inflammation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CD40, TP-03 is thought to modulate the immune response and potentially treat various inflammatory conditions.","oneSentence":"TP-03 is a monoclonal antibody targeting the CD40 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:32.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"}]},"trialDetails":[{"nctId":"NCT05454956","phase":"PHASE2","title":"Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD","status":"COMPLETED","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2022-08-03","conditions":"Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation","enrollment":39},{"nctId":"NCT05629390","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study","status":"COMPLETED","sponsor":"LianBio LLC","startDate":"2022-10-23","conditions":"Blepharitis","enrollment":163},{"nctId":"NCT05138861","phase":"PHASE1","title":"A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects","status":"COMPLETED","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2021-02-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT06054217","phase":"PHASE2","title":"Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2023-08-01","conditions":"Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis","enrollment":36},{"nctId":"NCT04475432","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis","status":"COMPLETED","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2020-09-09","conditions":"Blepharitis","enrollment":421},{"nctId":"NCT04784091","phase":"PHASE3","title":"Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis","status":"COMPLETED","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2021-04-29","conditions":"Blepharitis","enrollment":412}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TP-03","genericName":"TP-03","companyName":"Tarsus Pharmaceuticals, Inc.","companyId":"tarsus-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TP-03 is a monoclonal antibody targeting the CD40 receptor. Used for Dry eye disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}